Comparing the current results to its competitors, Ars Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 114.15 % year on year. The sales growth was above Ars Pharmaceuticals Inc 's competitors' average revenue growth of 13.07 %, achieved in the same quarter.
Ars Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 4.12 %
July 18, 2025
: Anaphylaxis, a severe and life-threatening allergic reaction, requires immediate intervention with epinephrine to prevent severe progression. Traditionally delivered via auto-injectors, epinephrine administration is now made easier with the introduction of EURneffy, an innovative adrenaline nasal spray. Recent approvals in the U.K. and compelling trial results have positioned EURneffy as a promising alternative to needle-based treatments, addressing common barriers to effective management of anaphylaxis. Anaphylaxis, characterized by rapid onset and potentially fatal symptoms, demands immediate treatment with epinephrine. Traditionally, this has been administered using needle-based auto-injectors, which...
September 23, 2024
: In a landmark development within the pharmaceutical landscape, ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray), marking its position as the first and only needle-free treatment specifically designed for Type I allergic reactions, including anaphylaxis. This article synthesizes critical information from the recent announcements to assess the potential impact on patient care, the pharmaceutical market, and ARS Pharmaceuticals strategic positioning.Anaphylaxis, a rapid and severe allergic reaction, necessitates immediate treatment to prevent life-threatening consequences. Historically, epinephrine has been administered via intramuscular injection, posing challenges for p...
June 28, 2024
In an industry where innovation progresses at every turn, ARS Pharmaceuticals has emerged as a significant player with its revolutionary product, EURneffy. This adrenaline nasal spray, recently recommended for approval by the Committee for Medicinal Products for Human Use (CHMP), stands poised to become the first and only needle-free option for emergency treatment of allergic reactions (anaphylaxis) in Europe. Meanwhile, ARS Pharmaceuticals reported their Q2 2023 revenue figures, reflecting a stable financial outlook when compared to their competitors. EURneffy: A Pioneering Solution for AnaphylaxisAnaphylaxis is a rapid-onset allergic reaction that can be life-threatening if not immediately treated. Curren...
February 20, 2024
This article aims to present the findings of a repeat dosing study on neffy (Epinephrine Nasal Spray) conducted under nasal allergen challenge conditions. The study results highlight the pharmacokinetic and pharmacodynamic profiles of neffy, comparing them to injectable formulations. Additionally, this article will briefly discuss the revenue growth reported by Ars Pharmaceuticals Inc, a key player in the pharmaceutical industry.Repeat Dosing Study:The topline results of the repeat dosing study indicate that neffy demonstrates a pharmacokinetic profile that is either greater than or similar to injection. This finding is crucial as it suggests that neffy can achieve comparable or more effective drug delivery...
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
Sources:
Ars Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ars Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
